Here are the most and least likely M&A targets in biotech, according to Truist
Source: SeekingAlpha
2025-12-23 13:26:50 ET
More on Abivax, Revolution Medicines, etc.
- Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy
- Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026
- Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call - Slideshow
- Abivax is the top performing biotechnology stock YTD
- Sagimet rises as licensing deal with Teva unit targets Madrigal drug
Read the full article on Seeking Alpha
For further details see:
Here are the most and least likely M&A targets in biotech, according to Truist
Janux Therapeutics Inc.
NASDAQ: JANX
JANX Trading
-0.68% G/L:
$14.64 Last:
514,387 Volume:
$14.74 Open:
JANX Latest News
May 07, 2026 04:01:00 pm
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
April 27, 2026 04:01:00 pm
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
April 16, 2026 04:01:00 pm
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
JANX Stock Data
$789,139,228
45,531,890
1.75%
55
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
